JP2016512514A - チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 - Google Patents
チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 Download PDFInfo
- Publication number
- JP2016512514A JP2016512514A JP2016501053A JP2016501053A JP2016512514A JP 2016512514 A JP2016512514 A JP 2016512514A JP 2016501053 A JP2016501053 A JP 2016501053A JP 2016501053 A JP2016501053 A JP 2016501053A JP 2016512514 A JP2016512514 A JP 2016512514A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- aromatic
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780099P | 2013-03-13 | 2013-03-13 | |
| US61/780,099 | 2013-03-13 | ||
| PCT/US2014/022750 WO2014164543A1 (en) | 2013-03-13 | 2014-03-10 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088243A Division JP6670885B2 (ja) | 2013-03-13 | 2018-05-01 | チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512514A true JP2016512514A (ja) | 2016-04-28 |
| JP2016512514A5 JP2016512514A5 (cg-RX-API-DMAC7.html) | 2017-05-18 |
Family
ID=51529943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501053A Withdrawn JP2016512514A (ja) | 2013-03-13 | 2014-03-10 | チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 |
| JP2018088243A Active JP6670885B2 (ja) | 2013-03-13 | 2018-05-01 | チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088243A Active JP6670885B2 (ja) | 2013-03-13 | 2018-05-01 | チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9216993B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2968342B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2016512514A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150130389A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105188705A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014249233A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015022602A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2904612A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL241193A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015011576A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014164543A1 (cg-RX-API-DMAC7.html) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019517548A (ja) * | 2016-06-10 | 2019-06-24 | ヴァイティー ファーマシューティカルズ,エルエルシー | メニン−mll相互作用の阻害剤 |
| WO2019189732A1 (ja) * | 2018-03-30 | 2019-10-03 | 大日本住友製薬株式会社 | 光学活性な架橋型環状2級アミン誘導体 |
| JP2019530745A (ja) * | 2016-09-14 | 2019-10-24 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン−mll相互作用の縮合二環式阻害剤 |
| JP2019532100A (ja) * | 2016-09-14 | 2019-11-07 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン−mll相互作用のスピロ二環式阻害剤 |
| JP2020514388A (ja) * | 2017-03-24 | 2020-05-21 | クラ オンコロジー,インク. | 血液悪性腫瘍およびユーイング肉腫を処置するための方法 |
| JP2021506882A (ja) * | 2017-12-20 | 2021-02-22 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン−mll相互作用のエキソ−アザスピロ阻害剤 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| US11530226B2 (en) | 2016-12-15 | 2022-12-20 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-MLL interaction |
| JP2023512113A (ja) * | 2019-11-29 | 2023-03-23 | 大鵬薬品工業株式会社 | Kras g12d変異に対して阻害活性を有する化合物 |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| JP2025501287A (ja) * | 2021-12-31 | 2025-01-17 | 成都先▲導▼▲薬▼物▲開▼▲発▼股▲フン▼有限公司 | Menin阻害剤及びその用途 |
| US12473295B2 (en) | 2019-12-19 | 2025-11-18 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6535430B2 (ja) * | 2012-09-28 | 2019-06-26 | イグニタ、インク. | 非定型プロテインキナーゼcのアザキナゾリン阻害薬 |
| AU2014249233A1 (en) | 2013-03-13 | 2015-09-24 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US10526341B2 (en) * | 2014-11-19 | 2020-01-07 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| WO2016197027A1 (en) * | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| TWI703150B (zh) * | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| AU2017212572A1 (en) * | 2016-01-26 | 2018-08-23 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| US10752639B2 (en) | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| WO2017161028A1 (en) * | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| CN109415337B (zh) | 2016-05-02 | 2022-01-18 | 密执安大学评议会 | 作为多发性内分泌腺瘤蛋白抑制剂的哌啶 |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| EA039109B1 (ru) * | 2016-12-07 | 2021-12-06 | Кура Онколоджи, Инк. | Мостиковые бициклические ингибиторы взаимодействия менин-mll и способы применения |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| EA038388B1 (ru) * | 2017-01-16 | 2021-08-19 | Кура Онколоджи, Инк. | Замещенные ингибиторы менина-mll и способы применения |
| EP3600313A4 (en) | 2017-03-31 | 2020-09-23 | The Regents of The University of Michigan | PIPERIDINES AS COVALENT MENINE INHIBITORS |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) * | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| CN110204552B (zh) * | 2018-02-28 | 2021-08-17 | 中国科学院上海药物研究所 | 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途 |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| US12662494B2 (en) | 2018-08-08 | 2026-06-23 | Sumitomo Pharma Co., Ltd. | Optically active bridged piperidine derivative |
| EP3860978A1 (en) | 2018-10-03 | 2021-08-11 | The Regents Of The University Of Michigan | Small molecule menin inhibitors |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| CA3116141C (en) * | 2018-12-06 | 2023-09-05 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
| ES2974634T3 (es) | 2018-12-21 | 2024-06-28 | Celgene Corp | Inhibidores de tienopiridinas de RIPK2 |
| ES2991429T3 (es) * | 2019-02-01 | 2024-12-03 | Univ South Carolina | Compuestos de piridina bicíclicos para su uso en el tratamiento del cáncer |
| BR112021024108A2 (pt) | 2019-05-31 | 2022-03-22 | Ikena Oncology Inc | Inibidores de tead e usos dos mesmos |
| US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| CN112116960B (zh) * | 2019-06-20 | 2024-10-11 | 中国石油化工股份有限公司 | 柴油加氢反应的组分含量确定方法、装置 |
| TW202126636A (zh) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | 作為menin抑制劑之六氫吡啶化合物 |
| MD4051678T2 (en) | 2019-10-28 | 2026-07-31 | Merck Sharp & Dohme Llc | Small molecule inhibitors of the KRAS G12C mutant |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| IL297039A (en) | 2020-04-07 | 2022-12-01 | Syndax Pharmaceuticals Inc | Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof |
| WO2021204159A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
| TW202204334A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| AR122159A1 (es) * | 2020-05-28 | 2022-08-17 | Novartis Ag | Inhibidores de mll1 y agentes antineoplásicos |
| EP4232020A4 (en) * | 2020-10-21 | 2024-08-07 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| BR112023021040A2 (pt) | 2021-05-08 | 2024-02-06 | Janssen Pharmaceutica Nv | Derivados espiro substituídos |
| EP4334310A1 (en) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
| AR125866A1 (es) | 2021-05-14 | 2023-08-23 | Syndax Pharmaceuticals Inc | Inhibidores de la interacción de menina-mll |
| CA3218479A1 (en) | 2021-06-01 | 2022-12-08 | Wei Cai | Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives |
| WO2022253289A1 (en) | 2021-06-03 | 2022-12-08 | Janssen Pharmaceutica Nv | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
| AU2022292697A1 (en) | 2021-06-17 | 2024-02-01 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| WO2023011446A1 (zh) * | 2021-08-04 | 2023-02-09 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
| WO2023215354A1 (en) * | 2022-05-03 | 2023-11-09 | Board Of Regents, The University Of Texas System | Menin proteolysis targeting chimeras (protacs) |
| US20260151399A1 (en) | 2022-11-24 | 2026-06-04 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| CN116199633B (zh) * | 2022-12-27 | 2024-05-31 | 甘肃省化工研究院有限责任公司 | 一种制备瑞维鲁胺的方法 |
| AR132185A1 (es) | 2023-03-24 | 2025-06-04 | Acerta Pharma Bv | COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013503906A (ja) * | 2009-09-04 | 2013-02-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 白血病を治療するための組成物および方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| AR073739A1 (es) * | 2008-09-10 | 2010-12-01 | Kalypsys Inc | Aminopirimidinas como inhibidores de los receptores de histamina |
| WO2011014128A1 (en) * | 2009-07-30 | 2011-02-03 | National University Of Singapore | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| AU2014249233A1 (en) | 2013-03-13 | 2015-09-24 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
-
2014
- 2014-03-10 AU AU2014249233A patent/AU2014249233A1/en not_active Abandoned
- 2014-03-10 US US14/203,233 patent/US9216993B2/en active Active
- 2014-03-10 EP EP14779908.4A patent/EP2968342B1/en active Active
- 2014-03-10 WO PCT/US2014/022750 patent/WO2014164543A1/en not_active Ceased
- 2014-03-10 CA CA2904612A patent/CA2904612A1/en not_active Abandoned
- 2014-03-10 MX MX2015011576A patent/MX2015011576A/es unknown
- 2014-03-10 CN CN201480025177.5A patent/CN105188705A/zh active Pending
- 2014-03-10 JP JP2016501053A patent/JP2016512514A/ja not_active Withdrawn
- 2014-03-10 KR KR1020157027855A patent/KR20150130389A/ko not_active Withdrawn
- 2014-03-10 BR BR112015022602A patent/BR112015022602A2/pt not_active IP Right Cessation
- 2014-03-10 US US14/773,686 patent/US9505781B2/en active Active
-
2015
- 2015-09-06 IL IL241193A patent/IL241193A0/en unknown
- 2015-11-10 US US14/937,421 patent/US9505782B2/en active Active
-
2016
- 2016-10-18 US US15/296,842 patent/US10160769B2/en active Active
-
2018
- 2018-05-01 JP JP2018088243A patent/JP6670885B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013503906A (ja) * | 2009-09-04 | 2013-02-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 白血病を治療するための組成物および方法 |
Non-Patent Citations (2)
| Title |
|---|
| BLOOD, vol. 120, no. 23, JPN6017045378, 2012, pages 4461 - 4469, ISSN: 0003689140 * |
| NATURE CHEMICAL BIOLOGY, vol. 8, no. 3, JPN6017045377, 2012, pages 277 - 284, ISSN: 0003689139 * |
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7461390B2 (ja) | 2016-06-10 | 2024-04-03 | ヴァイティー ファーマシューティカルズ,エルエルシー | メニン-mll相互作用の阻害剤 |
| JP2024045176A (ja) * | 2016-06-10 | 2024-04-02 | ヴァイティー ファーマシューティカルズ,エルエルシー | メニン-mll相互作用の阻害剤 |
| JP2019517548A (ja) * | 2016-06-10 | 2019-06-24 | ヴァイティー ファーマシューティカルズ,エルエルシー | メニン−mll相互作用の阻害剤 |
| JP2022058514A (ja) * | 2016-06-10 | 2022-04-12 | ヴァイティー ファーマシューティカルズ,エルエルシー | メニン-mll相互作用の阻害剤 |
| JP7007302B2 (ja) | 2016-06-10 | 2022-01-24 | ヴァイティー ファーマシューティカルズ,エルエルシー | メニン-mll相互作用の阻害剤 |
| JP7033141B2 (ja) | 2016-09-14 | 2022-03-09 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン-mll相互作用の縮合二環式阻害剤 |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| JP2019530745A (ja) * | 2016-09-14 | 2019-10-24 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン−mll相互作用の縮合二環式阻害剤 |
| JP2019532100A (ja) * | 2016-09-14 | 2019-11-07 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン−mll相互作用のスピロ二環式阻害剤 |
| US11220517B2 (en) | 2016-09-14 | 2022-01-11 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| US11530226B2 (en) | 2016-12-15 | 2022-12-20 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-MLL interaction |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| JP7749608B2 (ja) | 2017-03-24 | 2025-10-06 | クラ オンコロジー,インク. | 血液悪性腫瘍およびユーイング肉腫を処置するための方法 |
| JP2025098022A (ja) * | 2017-03-24 | 2025-07-01 | クラ オンコロジー,インク. | 血液悪性腫瘍およびユーイング肉腫を処置するための方法 |
| JP7628392B2 (ja) | 2017-03-24 | 2025-02-10 | クラ オンコロジー,インク. | 血液悪性腫瘍およびユーイング肉腫を処置するための方法 |
| JP2023055735A (ja) * | 2017-03-24 | 2023-04-18 | クラ オンコロジー,インク. | 血液悪性腫瘍およびユーイング肉腫を処置するための方法 |
| JP2020514388A (ja) * | 2017-03-24 | 2020-05-21 | クラ オンコロジー,インク. | 血液悪性腫瘍およびユーイング肉腫を処置するための方法 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| JP2021506882A (ja) * | 2017-12-20 | 2021-02-22 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン−mll相互作用のエキソ−アザスピロ阻害剤 |
| JP7307729B2 (ja) | 2017-12-20 | 2023-07-12 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン-mll相互作用のエキソ-アザスピロ阻害剤 |
| CN112105621A (zh) * | 2018-03-30 | 2020-12-18 | 大日本住友制药株式会社 | 光学活性桥型环状仲胺衍生物 |
| JPWO2019189732A1 (ja) * | 2018-03-30 | 2021-04-08 | 大日本住友製薬株式会社 | 光学活性な架橋型環状2級アミン誘導体 |
| CN112105621B (zh) * | 2018-03-30 | 2024-02-20 | 住友制药株式会社 | 光学活性桥型环状仲胺衍生物 |
| WO2019189732A1 (ja) * | 2018-03-30 | 2019-10-03 | 大日本住友製薬株式会社 | 光学活性な架橋型環状2級アミン誘導体 |
| JP7239562B2 (ja) | 2018-03-30 | 2023-03-14 | 住友ファーマ株式会社 | 光学活性な架橋型環状2級アミン誘導体 |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| JP2023512113A (ja) * | 2019-11-29 | 2023-03-23 | 大鵬薬品工業株式会社 | Kras g12d変異に対して阻害活性を有する化合物 |
| JP7707189B2 (ja) | 2019-11-29 | 2025-07-14 | 大鵬薬品工業株式会社 | Kras g12d変異に対して阻害活性を有する化合物 |
| US12473295B2 (en) | 2019-12-19 | 2025-11-18 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
| JP2025501287A (ja) * | 2021-12-31 | 2025-01-17 | 成都先▲導▼▲薬▼物▲開▼▲発▼股▲フン▼有限公司 | Menin阻害剤及びその用途 |
| JP7833041B2 (ja) | 2021-12-31 | 2026-03-18 | 成都先▲導▼▲薬▼物▲開▼▲発▼股▲フン▼有限公司 | Menin阻害剤及びその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL241193A0 (en) | 2015-11-30 |
| WO2014164543A1 (en) | 2014-10-09 |
| US20170253611A1 (en) | 2017-09-07 |
| KR20150130389A (ko) | 2015-11-23 |
| US9216993B2 (en) | 2015-12-22 |
| US20160137665A1 (en) | 2016-05-19 |
| EP2968342A1 (en) | 2016-01-20 |
| JP2018115214A (ja) | 2018-07-26 |
| US9505782B2 (en) | 2016-11-29 |
| BR112015022602A2 (pt) | 2017-07-18 |
| EP2968342A4 (en) | 2016-07-27 |
| EP2968342B1 (en) | 2018-10-03 |
| JP6670885B2 (ja) | 2020-03-25 |
| US9505781B2 (en) | 2016-11-29 |
| CA2904612A1 (en) | 2014-10-09 |
| US10160769B2 (en) | 2018-12-25 |
| US20140275070A1 (en) | 2014-09-18 |
| US20160046647A1 (en) | 2016-02-18 |
| AU2014249233A1 (en) | 2015-09-24 |
| MX2015011576A (es) | 2016-05-16 |
| CN105188705A (zh) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6670885B2 (ja) | チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 | |
| AU2020203464B2 (en) | Sulfonylureas and related compounds and use of same | |
| CN113811300B (zh) | Tead转录因子的新型小分子抑制剂 | |
| JP6759514B2 (ja) | ブロモドメインに対して活性な化合物 | |
| ES2398606T3 (es) | Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio | |
| ES2534227T3 (es) | Derivados de 4-aminopirimidina y su uso como antagonistas del receptor A2A de adenosina | |
| BR112020026748A2 (pt) | Inibidores de quinases dependentes de ciclina | |
| ES2351110T3 (es) | Compuestos de piperidinilamino-tieno[2,3-d]-pirimidina. | |
| JP4173191B2 (ja) | H3リガンドとして有用な3‐または4‐一置換フェノールおよびチオフェノール誘導体 | |
| RS63603B1 (sr) | Sredstva za indukciju apoptoze | |
| AU2014400628A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| JP2008514643A (ja) | 新規ピペリジニルアミノ−チエノ[2,3−d]ピリミジン化合物 | |
| CA3198096A1 (en) | Aryl derivatives for treating trpm3 mediated disorders | |
| AU2017327304B2 (en) | Use of morphinan derivative for therapeutic treatment of opioid δ receptor agonist-related disease | |
| BR112020019399A2 (pt) | Compostos macrocíclicos como inibidores de trk quinases | |
| CA2979758A1 (en) | New fyn kinase inhibitors | |
| KR20130005263A (ko) | 치환된 나프탈레닐-피리미딘 화합물 | |
| AU2022345092A1 (en) | Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof | |
| CN106986832A (zh) | Vegfr3抑制剂 | |
| JP2024540264A (ja) | ゴナドトロピン放出ホルモン拮抗剤及びその調製方法並びに使用 | |
| WO2021000957A1 (zh) | 一种杂环化合物、其药物组合物及用途 | |
| BR112017017610B1 (pt) | Composto de fórmula (ii) ou um sal ou solvato farmaceuticamente a c e i t á v e i s d o m e s m o , u s o d o c o m p o s t o o u d o s a l o u s o l v a t o farmaceuticamente aceitáveis e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170309 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170329 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171128 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180227 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20180522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180611 |